Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles

被引:30
作者
Koyama, Kazuya [1 ]
Ohshima, Nobuharu [2 ]
Suzuki, Junko [1 ]
Kawashima, Masahiro [1 ]
Takeda, Keita [1 ]
Ando, Takahiro [1 ]
Sato, Ryota [1 ]
Nagai, Hideaki [1 ]
Matsui, Hirotoshi [1 ]
Ohta, Ken [1 ,2 ]
机构
[1] Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Tokyo 2048585, Japan
[2] Natl Hosp Org Tokyo Natl Hosp, Ctr Asthma & Allergy, Tokyo 2048585, Japan
关键词
Chronic pulmonary aspergillosis; Maintenance treatment; Treatment duration; Recurrence; Anti-Aspergillus antibody; Triazole; CLINICAL CHARACTERISTICS; AZOLE RESISTANCE; FUMIGATUS; ITRACONAZOLE; DISEASES; SOCIETY;
D O I
10.1016/j.jiac.2014.02.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To assess the prevalence and risk factors of recurrence of chronic pulmonary aspergillosis (CPA) after discontinuation of antifungal triazoles. Method: We reviewed the medical records of CPA patients who achieved resolution of clinical and radiographic manifestations and stopped taking antifungal triazoles between June 2006 and June 2012 at Tokyo National Hospital. We evaluated whether there was CPA recurrence within 1 year after treatment cessation and investigated risk factors for relapse. The association of anti-Aspergillus antibody conversion with CPA recurrence was also reviewed. Results: A total of 39 patients were included in this study and there was CPA recurrence in 14 patients. Compared with the Non-recurrence group, the Recurrence group exhibited 1) younger age (p = 0.017), 2) more than one lung lobe affected by CPA more frequently (p = 0.008), 3) longer duration needed to remit manifestations of chest radiograph (p = 0.031), 4) longer antifungal treatment duration (p = 0.042). The present study did not reveal an association between negative conversion of serum anti-Aspergillus antibody and recurrence risk. Multivariate logistic regression analysis revealed that patients with CPA with affected area of more than one lung lobe had increased risk (odds ratio, 10.20; 95% confidence interval, 1.49-69.77; p = 0.018). Conclusion: CPA recurrence can be seen in about one-third of cases after discontinuing azole treatment. We should make decisions about treatment duration and follow up depending on the severity of each case, particularly on the expansion of CPA-affected area. (C) 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:375 / 379
页数:5
相关论文
共 18 条
  • [1] High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole
    Burgel, Pierre-Regis
    Baixench, Marie-Therese
    Amsellem, Michael
    Audureau, Etienne
    Chapron, Jeanne
    Kanaan, Reem
    Honore, Isabelle
    Dupouy-Camet, Jean
    Dusser, Daniel
    Klaassen, Corne H.
    Meis, Jacques F.
    Hubert, Dominique
    Paugam, Andre
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 869 - 874
  • [2] Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
    Cadranel, J.
    Philippe, B.
    Hennequin, C.
    Bergeron, A.
    Bergot, E.
    Bourdin, A.
    Cottin, V.
    Jeanfaivre, T.
    Godet, C.
    Pineau, M.
    Germaud, P.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (11) : 3231 - 3239
  • [3] TREATMENT OF PULMONARY ASPERGILLOMA WITH ITRACONAZOLE
    CAMPBELL, JH
    WINTER, JH
    RICHARDSON, MD
    SHANKLAND, GS
    BANHAM, SW
    [J]. THORAX, 1991, 46 (11) : 839 - 841
  • [4] CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186
  • [5] USE OF IMMUNODIFFUSION TEST IN SERODIAGNOSIS OF ASPERGILLOSIS
    COLEMAN, RM
    [J]. APPLIED MICROBIOLOGY, 1972, 23 (02) : 301 - &
  • [7] Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure
    Howard, Susan J.
    Cerar, Dasa
    Anderson, Michael J.
    Albarrag, Ahmed
    Fisher, Matthew C.
    Pasqualotto, Alessandro C.
    Laverdiere, Michel
    Arendrup, Maiken C.
    Perlin, David S.
    Denning, David W.
    [J]. EMERGING INFECTIOUS DISEASES, 2009, 15 (07) : 1068 - 1076
  • [8] Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis
    Jhun, Byung Woo
    Jeon, Kyeongman
    Eom, Jung Seop
    Lee, Ji Hyun
    Suh, Gee Young
    Kwon, O. Jung
    Koh, Won-Jung
    [J]. MEDICAL MYCOLOGY, 2013, 51 (08) : 811 - 817
  • [9] ITRACONAZOLE IN THE TREATMENT OF ASPERGILLOSIS - A STUDY OF 16 CASES
    LEBEAU, B
    PELLOUX, H
    PINEL, C
    MICHALLET, M
    GOUT, JP
    PISON, C
    DELORMAS, P
    BRU, JP
    BRION, JP
    AMBROISETHOMAS, P
    GRILLOT, R
    [J]. MYCOSES, 1994, 37 (5-6) : 171 - 179
  • [10] An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
    Limper, Andrew H.
    Knox, Kenneth S.
    Sarosi, George A.
    Ampel, Neil M.
    Bennett, John E.
    Catanzaro, Antonino
    Davies, Scott F.
    Dismukes, William E.
    Hage, Chadi A.
    Marr, Kieren A.
    Mody, Christopher H.
    Perfect, John R.
    Stevens, David A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (01) : 96 - 128